WITH ONE GIFT, YOU CAN SAVE TWO LIVES!
The Canines-N-Kids Foundation is committed to funding cutting edge research to help children and our canine best friends beat the devastating cancers they BOTH develop.
With one gift you can help us fund research that can help save two lives:
You can also to make a special Tribute Donation in honor of a special child or canine on our "Tribute Donation" page.
It feels great to know that #GivingOnceSavesTwice™! Thank you in advance for your generous support!
OPENING REMARKS 15 Minutes
KEYNOTE AND HISTORICAL PERSPECTVE (30 Minutes)
Peter Adamson, MD Past Chair of the Children’s Oncology Group (COG), Global Head, Oncology Drug Development & Lead, Pediatric Innovations Group, Sanofi, Inc; Dr. Adamson is Professor Emeritus at the Perelman School of Medicine of the University of Pennsylvania. He is Board Certified in Pediatric Hematology/Oncology and Clinical Pharmacology.
COMPARATIVE ONCOLOGY OVERVIEW (30 Minutes)
Significant challenges exist in oncology drug development. These are magnified when patient numbers are relatively small (as in pediatrics) and/or where the economics of developing drugs are challenging. This segment will provide an overview of traditional animal models in oncology drug development and introduce the potential inclusion of canine patient data to inform preclinical programs and to guide go/no-go decisions for clinical development. The challenges, limitations and opportunities will be framed, especially as they relate to translational value in development of new treatments for childhood cancer.
LAST REVISED: June 15, 2020
Canine Genetic Data in Context of Human (75 minutes)
DATA-DRIVEN COMPARATIVE ONCOLOGY RESEARCH: INTELLIGENT NTEGRATION OF HUMAN/PEDIATRIC AND CANINE CANCER DATA TO FUEL DISCOVERY & ACCELERATE DRUG DEVELOPMENT (75 Minutes)
Significant advances in comparative research hinge on adequately defined canine genomic and immunologic profiles (genomic sequencing, mutational load, and immunologic characterizations.) Efforts including the Precision Medicine and Moonshot Canine Immunotherapy initiatives are yielding exciting new datasets, which must be housed in an open-source environment (data commons) and harmonized to allow comparison/contrast with relevant human datasets. Here, leading experts provide insights into the status of various data generation and warehousing initiatives in the comparative context.
INDUSTRY PERSPECTIVES: UNITING HUMAN & ANIMAL PHARMA/BIOTECH TO STRENGTHEN & ACCELERATE DRUG DEVELOPMENT (60 minutes)
The engagement of drug developers is critical to accelerating progress in human (especially pediatric) and canine cancers. Here we cover the challenges of uniting human, animal pharma/biotech, present case studies to demonstrate real world examples and the utility and value of intelligent integration of canine patients into the drug development pipeline. We also hear from pharma and biotech what their needs are and how they envision receiving canine data that is useful to complement and inform their preclinical and clinical drug development plans, with a particular eye also to RACE Act requirements.
Discussant: Peter Adamson or possibly Will Eward, DVM, MD ?
GOLDEN RETRIEVER LIFETIME STUDY: REVIEW OF FIRST COHORT OF CANCER-AFFLICTED PARTICIPANTS (30 Minutes)
COURAGEOUS WARRIORS: CANCER PATIENTS’ PERSPECTIVES – (total 30 minutes – interspersed through program)
Cancer patients are the reason we are gathered. Cancer warriors (survivors of childhood cancer, and human advocate of a canine cancer warrior) will participate in a moderated panel discussion, providing personal insights on the needs of the patient.
COLLABORATIONS AT BOTH ENDS OF THE LEASH
Significant comparative research is underway which could inform and potentially advance our understanding of shared cancers in canines and in children and/or inform clinical trials of novel therapies or combinations for pediatric application. This section will include state of the art presentations regarding three major comparative cancers: osteosarcoma, brain cancers (notably gliomas) and lymphoma. Investigators involved in these critical projects will present updates on this ongoing research.
ONGOING COMPARATIVE INIITIATIVES RELEVANT TO CHILDHOOD CANCER L
Featured Young Investigator Mini-Presentations- 4 to be selected; 10 minutes each (Will be handled in Poster hall as features)
More great speakers added daily!
Dr. Patterson-Kane received her veterinary degree and PhD from Massey University, New Zealand. She completed specialty training in the field of veterinary anatomic pathology at the University of Florida followed by the University of Kentucky, before becoming board-certified in 1999. Dr. Patterson-Kane was a faculty member at the Royal Veterinary College (University of London), and then the University of Queensland (Australia), before holding the Chair in Veterinary Pathology at the University of Glasgow (United Kingdom). After leaving academia in 2014 she worked in private diagnostics and the biotechnology industry before joining the Morris Animal foundation as Chief Scientific Officer in 2019.
Dr. Patterson-Kane’s research interests are broad, including cellular stress and ageing, and cancer pathology. She is co-author of the only currently available equine oncology textbook, ‘Clinical Equine Oncology’.
|Operating System||Internet Explorer||Firefox||Chrome||Safari|
|Windows 7||IE8+||FF10+||Chrome15+||Windows 8||IE10||FF10+||Chrome15+|
|Mac OS X||FF10+||Chrome15+||Safari5.1+|
- For viewing Webinars:
- For viewing Virtual Events